companies making glp-1 drugs New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these at scale. Our FDA CRACKDOWN ESCALATES: 30 telehealth

A2AR antagonists triggered the AMPK/m-TOR autophagic pathway to reverse the calcium-dependent cell damage in 6-OHDA induced model of PD

P., Rosado, E

"This can be from inflammatory conditions like acne or eczema, injury to the skin, hormonal conditions, medications, and sunlight." This is because acne, sunlight, and skin rashes have the potential to stimulate melanocytes the pigment-making cells in the skin to make a surplus of pigment

The lyophilization process removes moisture while helping preserve peptide integrity during storage, allowing researchers to reconstitute the product according to their established laboratory protocols

Presented for research literature review only Zou P et al